Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO Trial
Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

**ECHO: Study Design**

**Study Design: ECHO Study**

- **Background**: Randomized, double-blind, phase 3 trial comparing rilpivirine and efavirenz in combination with a fixed background regimen consisting of tenofovir DF-emtricitabine in treatment-naïve HIV-infected patients.

- **Inclusion Criteria (n = 690)**
  - Antiretroviral-naïve patients
  - Age ≥ 18
  - HIV RNA ≥ 5000 copies/ml
  - No resistance to any study drugs

- **Treatment Arms**
  - Rilpivirine + Tenofovir DF-Emtricitabine
  - Efavirenz + Tenofovir DF-Emtricitabine

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Result

48 Week Virologic Response (ITT-TLOVR)

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Result

48 Week Virologic Failure and Discontinuations (ITT-TLOVR)

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Resistance Results

Incidence of NNRTI Resistance Associated Mutations (RAMs)

Interpretation: “Rilpivirine showed non-inferior efficacy compared with efavirenz, with a higher virological-failure rate, but a more favourable safety and tolerability profile.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.